Yue-Shan Ji, Yue Zeng, Shao-Fei Hu, Shu-Wang Li, Bei-Chen Zhang, Chang Liu, Hao-Chen Wu, An-Yang Wang, Zhao-Bing Gao, Yue Kong
{"title":"GluN1/GluN3A NMDA受体的ai增强虚拟筛选方法","authors":"Yue-Shan Ji, Yue Zeng, Shao-Fei Hu, Shu-Wang Li, Bei-Chen Zhang, Chang Liu, Hao-Chen Wu, An-Yang Wang, Zhao-Bing Gao, Yue Kong","doi":"10.1038/s41401-025-01644-1","DOIUrl":null,"url":null,"abstract":"<p><p>N-methyl-D-aspartate receptors (NMDARs) are calcium-permeable ionotropic glutamate receptors broadly expressed throughout the central nervous system, where they play crucial roles in neuronal development and synaptic plasticity. Among the various subtypes, the GluN1/GluN3A receptor represents a unique glycine-gated NMDAR with notably low calcium permeability. Despite its distinctive properties, GluN1/GluN3A remains understudied, particularly with respect to pharmacological tools development. This scarcity poses challenges for deeper investigation into its physiological functions and therapeutic relevance. In this study, we employed a hybrid virtual screening (VS) pipeline that integrates ligand-based and structure-based approaches for the efficient and precise identification of small-molecule candidates targeting GluN1/GluN3A. A large compound library comprising 18 million molecules was screened using an AI-enhanced multi-stage method. The initial phase utilized shape similarity ranking via ROCS-BART, followed by refinement with a graph neural network (GNN)-based drug-target interaction model to enhance docking accuracy. Functional validation using calcium flux (FDSS/μCell) identified two compounds with IC<sub>50</sub> values below 10 μM. Of these, one candidate exhibited potent inhibitory activity with an IC<sub>50</sub> of 5.31 ± 1.65 μM, which was further confirmed through manual patch-clamp recordings. These findings highlight an AI-enhanced VS workflow that achieves both efficiency and precision, providing a promising framework for exploring elusive targets such as GluN1/GluN3A.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AI-enhanced virtual screening approach to hit identification for GluN1/GluN3A NMDA receptor.\",\"authors\":\"Yue-Shan Ji, Yue Zeng, Shao-Fei Hu, Shu-Wang Li, Bei-Chen Zhang, Chang Liu, Hao-Chen Wu, An-Yang Wang, Zhao-Bing Gao, Yue Kong\",\"doi\":\"10.1038/s41401-025-01644-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>N-methyl-D-aspartate receptors (NMDARs) are calcium-permeable ionotropic glutamate receptors broadly expressed throughout the central nervous system, where they play crucial roles in neuronal development and synaptic plasticity. Among the various subtypes, the GluN1/GluN3A receptor represents a unique glycine-gated NMDAR with notably low calcium permeability. Despite its distinctive properties, GluN1/GluN3A remains understudied, particularly with respect to pharmacological tools development. This scarcity poses challenges for deeper investigation into its physiological functions and therapeutic relevance. In this study, we employed a hybrid virtual screening (VS) pipeline that integrates ligand-based and structure-based approaches for the efficient and precise identification of small-molecule candidates targeting GluN1/GluN3A. A large compound library comprising 18 million molecules was screened using an AI-enhanced multi-stage method. The initial phase utilized shape similarity ranking via ROCS-BART, followed by refinement with a graph neural network (GNN)-based drug-target interaction model to enhance docking accuracy. Functional validation using calcium flux (FDSS/μCell) identified two compounds with IC<sub>50</sub> values below 10 μM. Of these, one candidate exhibited potent inhibitory activity with an IC<sub>50</sub> of 5.31 ± 1.65 μM, which was further confirmed through manual patch-clamp recordings. These findings highlight an AI-enhanced VS workflow that achieves both efficiency and precision, providing a promising framework for exploring elusive targets such as GluN1/GluN3A.</p>\",\"PeriodicalId\":6942,\"journal\":{\"name\":\"Acta Pharmacologica Sinica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Pharmacologica Sinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41401-025-01644-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-025-01644-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
n -甲基- d -天冬氨酸受体(NMDARs)是广泛表达于整个中枢神经系统的钙渗透性离子性谷氨酸受体,在神经元发育和突触可塑性中起着至关重要的作用。在各种亚型中,GluN1/GluN3A受体代表一种独特的甘氨酸门控NMDAR,具有明显的低钙通透性。尽管具有独特的特性,GluN1/GluN3A仍未得到充分的研究,特别是在药理工具开发方面。这种稀缺性对其生理功能和治疗相关性的深入研究提出了挑战。在这项研究中,我们采用了一种混合虚拟筛选(VS)管道,结合了基于配体和基于结构的方法,高效、精确地鉴定靶向GluN1/GluN3A的小分子候选物。使用人工智能增强的多阶段方法筛选了包含1800万个分子的大型化合物库。初始阶段通过ROCS-BART进行形状相似性排序,随后使用基于图神经网络(GNN)的药物-靶点相互作用模型进行细化,以提高对接精度。利用钙通量(FDSS/μCell)进行功能验证,鉴定出两个IC50值小于10 μM的化合物。其中,一种候选物表现出强大的抑制活性,IC50为5.31±1.65 μM,通过人工膜片钳记录进一步证实了这一点。这些发现突出了人工智能增强的VS工作流程,实现了效率和精度,为探索GluN1/GluN3A等难以捉摸的目标提供了一个有希望的框架。
AI-enhanced virtual screening approach to hit identification for GluN1/GluN3A NMDA receptor.
N-methyl-D-aspartate receptors (NMDARs) are calcium-permeable ionotropic glutamate receptors broadly expressed throughout the central nervous system, where they play crucial roles in neuronal development and synaptic plasticity. Among the various subtypes, the GluN1/GluN3A receptor represents a unique glycine-gated NMDAR with notably low calcium permeability. Despite its distinctive properties, GluN1/GluN3A remains understudied, particularly with respect to pharmacological tools development. This scarcity poses challenges for deeper investigation into its physiological functions and therapeutic relevance. In this study, we employed a hybrid virtual screening (VS) pipeline that integrates ligand-based and structure-based approaches for the efficient and precise identification of small-molecule candidates targeting GluN1/GluN3A. A large compound library comprising 18 million molecules was screened using an AI-enhanced multi-stage method. The initial phase utilized shape similarity ranking via ROCS-BART, followed by refinement with a graph neural network (GNN)-based drug-target interaction model to enhance docking accuracy. Functional validation using calcium flux (FDSS/μCell) identified two compounds with IC50 values below 10 μM. Of these, one candidate exhibited potent inhibitory activity with an IC50 of 5.31 ± 1.65 μM, which was further confirmed through manual patch-clamp recordings. These findings highlight an AI-enhanced VS workflow that achieves both efficiency and precision, providing a promising framework for exploring elusive targets such as GluN1/GluN3A.
期刊介绍:
APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.